Filing Details
- Accession Number:
- 0001179110-18-012090
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-10-09 14:20:16
- Reporting Period:
- 2018-10-05
- Accepted Time:
- 2018-10-09 14:20:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1235007 | Endocyte Inc | ECYT | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1522046 | Beth Taylor | 3000 Kent Ave, Ste A1-100 West Lafayette IN 47906 | Vp Finance & Chief Acctg Offcr | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2018-10-05 | 7,022 | $15.56 | 56,341 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- Represents the sale of 7,022 shares in a multiple transactions, ranging in price from $15.1300 to $15.9200, resulting in a weighted-average sale price per share of $15.5635. The 7,022 shares were sold to cover taxes, commissions and fees associated with the October 4, 2018 settlement of 15,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold by Merrill Lynch pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934 adopted by the reporting person on July 30, 2018.